Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zhe Sheng

Showing results (581-590 of 633) with videos related to

Pageof 64
Sort By:
Molecular Pharmacology|May 3, 2019
Colchicine Binding Site Agent DJ95 Overcomes Drug Resistance and Exhibits Antitumor EfficacyKinsie E Arnst, Yuxi Wang, Zi-Ning Lei, et al.
Nature Communications|May 13, 2022
N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancerYutian Zou, Shaoquan Zheng, Xinhua Xie, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|December 18, 2022
The Single-Cell Landscape of Intratumoral Heterogeneity and The Immunosuppressive Microenvironment in Liver and Brain Metastases of Breast CancerYutian Zou, Feng Ye, Yanan Kong, et al.
The International Journal of Biochemistry & Cell Biology|April 15, 2014
Linsitinib (OSI-906) antagonizes ATP-binding cassette subfamily G member 2 and subfamily C member 10-mediated drug resistanceHui Zhang, Rishil J Kathawala, Yi-Jun Wang, et al.
Anticancer Research|September 10, 2014
Expression of ABCB6 is related to resistance to 5-FU, SN-38 and vincristineKentaro Minami, Youhei Kamijo, Yukihiko Nishizawa, et al.
Biochemical Pharmacology|July 4, 2012
OSI-930 analogues as novel reversal agents for ABCG2-mediated multidrug resistanceYe-Hong Kuang, Jay P Patel, Kamlesh Sodani, et al.
Molecular Cancer Therapeutics|March 8, 2017
The BTK Inhibitor Ibrutinib (PCI-32765) Overcomes Paclitaxel Resistance in ABCB1- and ABCC10-Overexpressing Cells and TumorsHui Zhang, Atish Patel, Yi-Jun Wang, et al.
Anti-Cancer Drugs|March 8, 2013
Bipiperidinyl derivatives of 23-hydroxybetulinic acid reverse resistance of HepG2/ADM and MCF-7/ADR cellsDong-Mei Zhang, Ying-Jie Li, Chang Shu, et al.
Cancer Medicine|February 12, 2019
Combined prognostic value of the cancer stem cell markers CD47 and CD133 in esophageal squamous cell carcinomaJian-Hua Wang, Shu-Ting Huang, Lan Zhang, et al.
Medcomm|February 14, 2025
Once-weekly glucagon-like peptide receptor agonist polyethylene glycol loxenatide protects against major adverse cardiovascular events in patients with type 2 diabetes: a multicenter ambispective cohort study (FLYING trial)Jilin Li, Yu Tian, Liping Li, et al.
Pageof 64

Showing results (581-590 of 633) with videos related to

Sort By:
Pageof 64
Molecular Pharmacology|May 3, 2019
Colchicine Binding Site Agent DJ95 Overcomes Drug Resistance and Exhibits Antitumor EfficacyKinsie E Arnst, Yuxi Wang, Zi-Ning Lei, et al.
Nature Communications|May 13, 2022
N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancerYutian Zou, Shaoquan Zheng, Xinhua Xie, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|December 18, 2022
The Single-Cell Landscape of Intratumoral Heterogeneity and The Immunosuppressive Microenvironment in Liver and Brain Metastases of Breast CancerYutian Zou, Feng Ye, Yanan Kong, et al.
The International Journal of Biochemistry & Cell Biology|April 15, 2014
Linsitinib (OSI-906) antagonizes ATP-binding cassette subfamily G member 2 and subfamily C member 10-mediated drug resistanceHui Zhang, Rishil J Kathawala, Yi-Jun Wang, et al.
Anticancer Research|September 10, 2014
Expression of ABCB6 is related to resistance to 5-FU, SN-38 and vincristineKentaro Minami, Youhei Kamijo, Yukihiko Nishizawa, et al.
Biochemical Pharmacology|July 4, 2012
OSI-930 analogues as novel reversal agents for ABCG2-mediated multidrug resistanceYe-Hong Kuang, Jay P Patel, Kamlesh Sodani, et al.
Molecular Cancer Therapeutics|March 8, 2017
The BTK Inhibitor Ibrutinib (PCI-32765) Overcomes Paclitaxel Resistance in ABCB1- and ABCC10-Overexpressing Cells and TumorsHui Zhang, Atish Patel, Yi-Jun Wang, et al.
Anti-Cancer Drugs|March 8, 2013
Bipiperidinyl derivatives of 23-hydroxybetulinic acid reverse resistance of HepG2/ADM and MCF-7/ADR cellsDong-Mei Zhang, Ying-Jie Li, Chang Shu, et al.
Cancer Medicine|February 12, 2019
Combined prognostic value of the cancer stem cell markers CD47 and CD133 in esophageal squamous cell carcinomaJian-Hua Wang, Shu-Ting Huang, Lan Zhang, et al.
Medcomm|February 14, 2025
Once-weekly glucagon-like peptide receptor agonist polyethylene glycol loxenatide protects against major adverse cardiovascular events in patients with type 2 diabetes: a multicenter ambispective cohort study (FLYING trial)Jilin Li, Yu Tian, Liping Li, et al.
Pageof 64